IONS:NGS-Ionis Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 41.59

Change

0.00 (0.00)%

Market Cap

USD 5.29B

Volume

0.56M

Analyst Target

USD 68.11
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ionis Pharmaceuticals Inc is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
BNTX BioNTech SE

N/A

USD 22.34B
ARGX argenx NV ADR

N/A

USD 22.28B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 19.03B
GMAB Genmab AS

N/A

USD 18.26B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing IONS

ARKG 0.00 % 0.75 %

N/A

N/A
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.79% 39% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.79% 39% F 28% F
Trailing 12 Months  
Capital Gain 17.59% 74% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.59% 74% C 73% C
Trailing 5 Years  
Capital Gain -44.08% 61% D- 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.08% 61% D- 28% F
Average Annual (5 Year Horizon)  
Capital Gain -4.56% 53% F 34% F
Dividend Return -4.56% 52% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.57% 95% A 71% C-
Risk Adjusted Return -19.37% 46% F 31% F
Market Capitalization 5.29B 96% N/A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 524.14 2% 2%
Price/Book Ratio 15.74 9% 7%
Price / Cash Flow Ratio -19.71 92% 88%
Price/Free Cash Flow Ratio -22.08 96% 90%
Management Effectiveness  
Return on Equity -76.34% 50% 24%
Return on Invested Capital -22.49% 78% 33%
Return on Assets -7.51% 91% 37%
Debt to Equity Ratio 317.96% 3% 7%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector